News for Organovo Holdings, Inc. (0R02.L)

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. ( ONVO) (the ”œCompany”) announced that it will carry forward its 3D bioprinting and

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-i...

Organovo Holdings, Inc. secures financial stability through strategic sale. Sale of FXR Program to Lilly supports advancements in treatments. Project

Organovo Holdings, Inc. reports a strong end-of-year cash position. Expected milestone payment to enhance financial stability. Strategic developments

**media[589169]**

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnolo...

**media[578295]**

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 200 points on Wednesday. The Dow traded up 0.55% to 41,808.59 while the...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Wednesday. Following the market opening Wednesday, the Dow traded up 0.56%...

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. ( ONVO), a clinical stage biotechnology company focused on developing novel treatment ap

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ( American: MTNB) today announced the appointment of biotech industry ve

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.46% to 43,661.51 while t...

February 25, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.14% to 43,401.71 while the NAS...

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (ONVO) (”œOrganovo” or the ”œCompany”), a clinical stage biotechnology company focu

**media[549780]**

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a notable transaction by acquiring an additional 482,684 shares of Organovo Holdings I

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (ONVO), a clinical stage biotechnology company focused on developing novel treatment appr

**media[506814]**